Atherosclerosis treatment has moved far beyond simply unclogging arteries. The disease, driven by a buildup of fatty plaques inside artery walls, is now treated with a layered strategy that combines cholesterol-lowering drugs, anti-inflammatory medications, blood-thinning agents, lifestyle changes, and, when necessary, surgical procedures to restore blood flow. What makes the modern approach genuinely different from a generation ago is the evidence that aggressive treatment can not only slow plaque growth but actually shrink plaques and make them less likely to rupture, which is what triggers most heart attacks and strokes.
Why Lowering Cholesterol Is Still the Foundation
Statins remain the first-line drug for treating atherosclerosis, and their track record across decades of clinical trials is hard to argue with. They work primarily by blocking cholesterol production in the liver, but their benefits go beyond just dropping LDL numbers. Intensive statin therapy can stabilize dangerous plaques by shrinking the fatty core inside them, reducing inflammation in the artery wall, and improving how the inner lining of blood vessels functions.1PubMed Central. Stabilization of high-risk plaques That said, statins alone leave a substantial chunk of risk on the table. Researchers call this “residual risk,” and much of the progress in atherosclerosis treatment over the past decade has been about chipping away at it with additional therapies.
For people who cannot reach low enough cholesterol levels on statins alone, ezetimibe is often the next drug added. It works differently, blocking cholesterol absorption in the intestine rather than its production in the liver. A landmark trial of over 18,000 patients who had recently suffered a heart event found that adding ezetimibe to a statin brought the average LDL cholesterol down to about 54 mg/dL compared with roughly 70 mg/dL on the statin alone. Over seven years, that translated to a modest but real reduction in major cardiovascular events.2PubMed. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes The takeaway reinforced a principle that runs through modern atherosclerosis care: the lower the LDL, the better the outcomes, with no obvious floor where the benefit stops.
PCSK9 Inhibitors and the Push Toward Ultra-Low LDL
When statins plus ezetimibe still are not enough, PCSK9 inhibitors represent the next escalation. These drugs, which include the injectable antibodies evolocumab and alirocumab, and a newer RNA-based injection called inclisiran, work by blocking a protein that normally recycles LDL receptors on liver cells. With that protein out of the way, the liver pulls much more LDL out of the bloodstream. The effect is dramatic: PCSK9 inhibitors lower LDL cholesterol and other harmful lipoproteins, including apolipoprotein B and lipoprotein(a).3PubMed. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
More interesting than the cholesterol numbers alone is what these drugs do to actual plaques. Imaging studies have shown that combining statins with PCSK9 inhibitors promotes plaque stability in patients who have had a recent heart event, and the degree of plaque improvement tracks closely with how low LDL levels go.4PubMed Central. PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring? These are not just lab values changing on a report. The fatty, vulnerable deposits inside coronary arteries genuinely become smaller and more stable.
The main barrier is not effectiveness but access. In the United States, health insurers frequently impose prior authorization requirements, step therapy mandates, and complex appeals processes before covering PCSK9 inhibitors. These restrictions have been shown to hurt medication adherence, meaning even patients who are prescribed these drugs often stop taking them or never fill the prescription.5PubMed Central. Adherence to PCSK9 Inhibitors in Clinical Practice Systematic Review and Meta-Analysis of Observational Studies Inclisiran, which only needs to be injected twice a year after an initial loading period, may help with adherence, but insurance hurdles remain a real-world obstacle.
Can Atherosclerosis Actually Reverse?
This is probably the question people most want answered, and the evidence says yes, to a degree. A systematic review and meta-analysis of 29 imaging studies found that lipid-lowering therapy significantly reduced the total volume of coronary plaque.6Scientific Reports. The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis And the combination of statins with ezetimibe and PCSK9 inhibitors consistently produces both shrinkage in plaque size and favorable changes in plaque composition, meaning the plaques that remain become more fibrous and stable rather than soft and rupture-prone.7PubMed Central. Lipid-lowering Therapy and Coronary Plaque Regression
One small trial tested an intensive lipid-lowering regimen and measured plaque volume by ultrasound at 90 days. The intensive group saw an average decrease in total plaque volume of about 5%, while the standard-treatment group saw a slight increase.8PubMed. Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER) That is a short timeframe for a disease that builds over decades, and the difference did not reach conventional statistical significance in that trial, but the direction is consistent with the larger body of evidence. The honest framing is this: aggressive treatment can measurably shrink plaques and make them less dangerous, but it does not restore arteries to a pristine, teenage state. The goal is stabilization and partial regression, not cure.
Targeting Inflammation Directly
One of the most important shifts in atherosclerosis treatment is the recognition that the disease is fundamentally inflammatory. The fatty buildup in artery walls triggers an ongoing immune response, and that inflammation is what makes plaques unstable and prone to rupturing. Endothelial dysfunction, the failure of the artery’s inner lining to function properly, is increasingly understood as a central driver of this process.9PubMed Central. Endothelial Dysfunction in Atherosclerosis: Experimental Models and Therapeutics
This insight has led to anti-inflammatory treatments being tested alongside traditional cholesterol drugs. The most clinically advanced is low-dose colchicine, a cheap, old drug originally used for gout. In patients already on standard therapy including statins, adding just half a milligram of colchicine daily reduced major cardiovascular events by about 31% in those with stable atherosclerosis and by about 23% after a recent heart attack.10PubMed. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease That is a striking benefit from a drug that does nothing to cholesterol levels, and it underscores that atherosclerosis treatment is no longer just about lipids.
Blood Thinners and the Dual Pathway Approach
Atherosclerotic plaques do their worst damage when they rupture and trigger a blood clot that blocks an artery. Antiplatelet drugs like aspirin have long been a cornerstone of prevention for exactly this reason. But a newer strategy combines low-dose aspirin with a very low dose of rivaroxaban, an anticoagulant, to attack clot formation from two different angles: aspirin dampens platelet activation while rivaroxaban tamps down thrombin, a key clotting protein.11PubMed. Rivaroxaban plus aspirin for cardiovascular protection This combination has been approved for secondary prevention in people with coronary or peripheral artery disease.
The tradeoff, as with any blood-thinning strategy, is bleeding risk. In a study of patients who had undergone procedures for peripheral artery disease, the rivaroxaban-plus-aspirin group had fewer cardiovascular events but roughly two and a half times the rate of major bleeding compared with dual antiplatelet therapy alone.12PubMed Central. Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease Deciding whether the net benefit is worth it requires weighing individual bleeding risk against the severity of atherosclerotic disease, which is why this approach is not used across the board.
Triglycerides, Omega-3s, and Icosapent Ethyl
For years, fish oil supplements have been marketed with vague claims about heart health, and most large trials of standard fish oil have been underwhelming. Icosapent ethyl is a different story. It is a prescription, purified form of the omega-3 fatty acid EPA, given at high doses. In a major trial of patients who had elevated triglycerides and either existing cardiovascular disease or diabetes with additional risk factors, icosapent ethyl significantly reduced cardiovascular events on top of well-controlled LDL cholesterol.13PubMed. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention
What makes this finding especially interesting is that the benefit was likely not just about triglyceride lowering. The drug appears to work through additional mechanisms, possibly anti-inflammatory or plaque-stabilizing effects, though the exact pathways are still being studied.14PubMed. Cardiovascular risk reduction with icosapent ethyl This is worth noting because over-the-counter fish oil capsules are not the same product, do not contain the same formulation, and have not shown similar results. The distinction between prescription icosapent ethyl and drugstore fish oil matters.
Diabetes Drugs That Protect Arteries
Two classes of diabetes medications have turned out to have substantial cardiovascular benefits that go beyond blood sugar control. GLP-1 receptor agonists, drugs like semaglutide and liraglutide, and SGLT2 inhibitors such as empagliflozin and dapagliflozin have both shown significant reductions in major cardiovascular events and heart failure hospitalizations across multiple large trials.15PubMed. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes These drugs are increasingly used not just for diabetes management but explicitly for cardiovascular protection in patients with or at high risk for atherosclerotic disease. The cardiovascular benefit appears to involve anti-inflammatory effects, improved endothelial function, and favorable changes in body composition, though no single mechanism fully explains the results.
Diet and Exercise Still Matter
No medication discussion should overshadow the fact that lifestyle changes have measurable effects on atherosclerosis itself, not just on risk factors. A randomized trial comparing a Mediterranean diet to a low-fat diet in people with coronary heart disease found that the Mediterranean diet actually decreased carotid artery wall thickness over five and seven years, while the low-fat diet did not change it.16PubMed Central. Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease That is not a surrogate marker buried in a lab report. Carotid intima-media thickness is a direct physical measurement of how much disease is in the artery wall, and the Mediterranean diet measurably reduced it. The implication is that dietary pattern, not just calorie restriction or any single nutrient, influences whether plaques grow or stabilize. Regular physical activity, smoking cessation, and blood pressure control round out the lifestyle pillars, each with strong independent evidence for slowing or partially reversing atherosclerotic progression.
When Arteries Need to Be Opened
Despite the best medications, some patients develop blockages severe enough to restrict blood flow and cause symptoms like chest pain or leg pain with walking. In these cases, revascularization, physically restoring flow through or around a blocked artery, becomes necessary. The two main approaches are percutaneous coronary intervention (placing a stent through a catheter) and coronary artery bypass grafting (surgically rerouting blood around blockages using a vessel from elsewhere in the body). Long-term data comparing the two approaches for certain anatomies, such as blockages in the left main coronary artery, show tradeoffs: stenting is less invasive with faster recovery, while bypass surgery has shown durability advantages in complex, multi-vessel disease.17PubMed. 10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease
Atherosclerosis is not limited to the heart. Peripheral artery disease, which affects the legs and feet, and carotid artery disease, which affects the vessels supplying the brain, both require their own revascularization decisions. For peripheral arteries, the general approach is to use catheter-based treatments like angioplasty and stenting for shorter, less complex blockages, which achieve roughly 80% patency at five years with lower morbidity than open surgery. Surgical bypass is reserved for longer or more complex lesions, though endovascular techniques are increasingly being tried even in advanced disease as the technology improves.18Radcliffe Cardiology. Non-coronary Interventions: An Introduction to Peripheral Arterial Interventions
Biomarkers and Risk Scoring
Knowing who to treat aggressively matters almost as much as knowing what to treat with. Traditional risk calculators use factors like age, blood pressure, cholesterol, and smoking status, but they misclassify a meaningful number of people, particularly those at intermediate risk. Two additional tools have proven useful for refining these estimates: high-sensitivity C-reactive protein (hs-CRP), a blood marker of inflammation, and coronary artery calcium scoring, a quick CT scan that quantifies the amount of calcified plaque in the heart’s arteries. Both add real predictive value beyond standard risk factors.19PubMed. Risk Stratification for Primary Prevention of Coronary Artery Disease European guidelines now state that calcium scoring may be used to improve risk classification around treatment decision thresholds, particularly for people where the decision to start a statin is uncertain.20PubMed Central. Subclinical Hypertension-Mediated Organ Damage (HMOD) in Hypertension
Machine learning models that integrate clinical data with genomic, proteomic, and metabolomic information are starting to outperform conventional risk scores in research settings.21medRxiv. Advancing cardiovascular disease risk prediction beyond conventional methods Whether these tools make it into routine clinical practice depends on cost, accessibility, and validation across diverse populations, but the direction is clear: risk prediction is moving from a handful of checklist items toward more personalized, multi-layered profiling.
Sex Differences in Plaque Behavior
Atherosclerosis does not play out identically in men and women. In younger women, the culprit behind a heart event is more often plaque erosion, where the surface of the plaque wears away, rather than the dramatic rupture that is more common in men. As women age, particularly after menopause, the pattern shifts: plaque rupture becomes more frequent, and plaques become more vulnerable.22PubMed. Sex Differences in Culprit Plaque Characteristics Among Different Age Groups in Patients With Acute Coronary Syndromes In men, by contrast, the proportion of events caused by rupture stays relatively stable across age groups, while erosion decreases and calcified nodules become more common with age.
The good news from imaging data is that when it comes to the rate at which plaques grow and how effectively lipid-lowering therapy shrinks them, no significant differences have been found between men and women after correcting for known risk factors. Risk factor modification appears to be equally effective regardless of sex.23Atherosclerosis. Sex-related differences in atherosclerotic plaque characteristics and progression in carotid and coronary arteries The implication is not that sex does not matter in atherosclerosis treatment but that the differences are more about plaque morphology and the mechanism behind acute events than about whether the treatments themselves work. Recognizing these differences helps clinicians choose the right interventions and not dismiss atypical presentations, which has historically been a problem in women’s cardiovascular care.
Lipoprotein(a) and the Next Frontier in Drug Therapy
Lipoprotein(a), often written as Lp(a), is a genetically determined particle in the blood that raises cardiovascular risk independently of LDL cholesterol. Until recently, nothing could effectively lower it. That is changing fast. A family of RNA-based drugs, including olpasiran, lepodisiran, and zerlasiran, have shown the ability to reduce Lp(a) levels by over 90% in clinical trials.24PubMed Central. Current Clinical Trials for Treating Elevated Lipoprotein(a) In a dose-ranging study of olpasiran, the highest doses essentially eliminated Lp(a) from the bloodstream, with reductions exceeding 97% compared with placebo.25PubMed. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
These are still investigational drugs, and the critical question remains unanswered: does dramatically lowering Lp(a) actually prevent heart attacks and strokes? Large outcome trials are underway. If the results are positive, Lp(a)-targeting therapy would open up treatment for a population that currently has an elevated risk factor they can do essentially nothing about, since neither diet, exercise, nor statins meaningfully budge Lp(a) levels.
Gene Editing and Resolution-Based Therapies
Further out on the horizon, gene-editing approaches are being tested with striking early results. In a primate study, a single infusion of lipid nanoparticles carrying a base-editing tool nearly completely knocked out the PCSK9 gene in the liver. Blood levels of PCSK9 protein dropped by about 90%, and LDL cholesterol fell by roughly 60%, with both changes remaining stable for at least eight months after just one treatment.26Nature. In vivo base editing of PCSK9 durably lowers cholesterol in primates If this could be safely translated to humans, it would mean a one-time treatment replacing a lifetime of injections or pills. Human trials are in early stages, and the usual cautions about safety, off-target editing, and long-term durability apply.
A separate line of research is exploring resolution-based therapies, which aim to help the body’s own immune system clean up diseased arteries more effectively. In healthy arteries, immune cells called macrophages routinely swallow dead cells and debris, a process called efferocytosis. In advanced plaques, this cleanup system breaks down, leading to a buildup of dead cell material that destabilizes the plaque. Experimental treatments using specialized pro-resolving mediators, peptides, and metabolites are being developed to restart this process, essentially helping the body resolve inflammation rather than just suppressing it. Vaccine-based approaches that train the immune system to target atherosclerosis-specific molecules are also in early development.27PubMed Central. Anti-Atherogenic Mechanisms and Therapies These are still preclinical or very early-stage clinical concepts, but they represent a fundamentally different philosophy from current treatments: instead of adding external drugs to counteract the disease, the idea is to restore the body’s own resolution machinery.